Is GeoVax Labs, Inc. overvalued or undervalued?

As of 12 November 2024, GeoVax Labs, Inc. has seen its valuation grade change from does not qualify to risky, indicating a significant shift in its perceived financial health. The company is currently considered overvalued, particularly given its troubling financial metrics. Notably, the Price to Book Value stands at 2.15, while both the EV to EBIT and EV to EBITDA ratios are at -0.39, reflecting negative earnings performance.
In comparison to its peers, GeoVax's financial ratios are concerning. For instance, Catalyst Biosciences, Inc. is classified as expensive with a P/E ratio of 90.02, while Elutia, Inc. is also risky with an EV to EBITDA of -4.64. Additionally, GeoVax's return metrics are alarming, with a year-to-date decline of 64.58% compared to a modest 2.44% gain in the S&P 500, reinforcing the notion that the stock is significantly underperforming relative to broader market trends.